Novavax, Sanofi to Co-commercialize COVID-19 Vaccine, Develop Novel COVID-19-Influenza Combo

 

• Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards
• Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties
• Novavax is entitled to additional launch and sales milestone opportunities of up to $200 million, plus mid-single digit royalties, for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M™ adjuvant technology
• Accelerates potential for development of a novel COVID-19-Influenza combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering individuals enhanced convenience and protection

https://www.biospace.com/article/releases/novavax-and-sanofi-announce-co-exclusive-licensing-agreement-to-co-commercialize-covid-19-vaccine-and-develop-novel-covid-19-influenza-combination-vaccines/